13436-14-1

Basic information

• Product Name: ethyl 4-hydroxy-6,7-dimethoxyquinoline-3-carboxylate
• Synonyms: 4-Hydroxy-6,7-dimethoxy-quinoline-3-carboxylic acid ethyl ester
• CAS NO: 13436-14-1
• Molecular Formula: C₁₄H₁₅NO₅
• Molecular Weight: 277.2726
• Mol File: 13436-14-1.mol
• Article Data: 19

Chemical Properties

• Appearance: /
• CAS DataBase Reference: ethyl 4-hydroxy-6,7-dimethoxyquinoline-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-hydroxy-6,7-dimethoxyquinoline-3-carboxylate(13436-14-1)
• EPA Substance Registry System: ethyl 4-hydroxy-6,7-dimethoxyquinoline-3-carboxylate(13436-14-1)

Safety Data

• Hazardous Substances Data: 13436-14-1(Hazardous Substances Data)

Upstream product

• 26717-39-5 [[(3,4-Dimethoxyphenyl)amino]methylene]malonic acid,diethyl ester 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 
• 6315-89-5 3,4-dimethoxyaniline 
• 5231-87-8 3,4-diethoxy-3-cyclobuten-1,2-dione 

Downstream Products

• 417722-21-5 5-((6,7-dimethoxyquinolin-4-yl)oxy)pyridine-2-amine 
• 190727-05-0 N-{4-[(6,7-Dimethoxy-4-quinolinyl)oxy]phenyl}-(4-nitrophenyl)carboxamide 
• 190726-66-0 Ki₆₉₄₅ 

Relevant articles and documents

Structural development of a type-1 ryanodine receptor (RyR1) Ca2+-release channel inhibitor guided by endoplasmic reticulum Ca2+ assay

Type-1 ryanodine receptor (RyR1) is a calcium-release channel localized on sarcoplasmic reticulum (SR) of the skeletal muscle, and mediates muscle contraction by releasing Ca2+ from the SR. Genetic mutations of RyR1 are associated with skeletal muscle diseases such as malignant hyperthermia and central core diseases, in which over-activation of RyR1 causes leakage of Ca2+ from the SR. We recently developed an efficient high-throughput screening system based on the measurement of Ca2+ in endoplasmic reticulum, and used it to identify oxolinic acid (1) as a novel RyR1 channel inhibitor. Here, we designed and synthesized a series of quinolone derivatives based on 1 as a lead compound. Derivatives bearing a long alkyl chain at the nitrogen atom of the quinolone ring and having a suitable substituent at the 7-position of quinolone exhibited potent RyR1 channel-inhibitory activity. Among the synthesized compounds, 14h showed more potent activity than dantrolene, a known RyR1 inhibitor, and exhibited high RyR1 selectivity over RyR2 and RyR3. These compounds may be promising leads for clinically applicable RyR1 channel inhibitors.

ANTIVIRAL AGENTS

The present invention is directed to compounds that are antiviral agents. Specificially the compounds of the present invention inhibit replication of HCV and are therefore useful in treating hepatitis C infections. The present invention is also directed t

ETHER-LINKED HETEROARYL COMPOUNDS

Compounds of formula (I) are disclosed, as well as methods for synthesizing such compounds and methods of their use. Preferred compounds of formula (I) are potent inhibitors of c-MET/HGFR useful in the treatment of a variety of HGFR-mediated disorders, including cancers.